Ibrutinib in front line elderly - Dr Sharman's... - CLL Support

CLL Support

23,340 members40,049 posts

Ibrutinib in front line elderly - Dr Sharman's latest blog on how CLL/SLL patients over 65 fared in a multicentre trial

AussieNeil profile image
AussieNeilPartnerAdministrator
1 Reply

Dr Sharman summarises his experience of the outcome of an open label, phase 1b/2 trial on 31 previously untreated patients (29 with CLL and 2 with SLL) between 65 and 84 years old (average age 71) that required therapy.

After a median follow-up of 22·1 months, 71% of 31 patients achieved an objective response, 13% had a complete response, one patient (3%) had a nodular partial response, and 17 (55%) patients had a partial response.

For the complete summary, which includes side effects experienced and their severity,

cll-nhl.com/2013/12/ibrutin...

This was termed a phase 1b/2 trial because "Patients received 28 day cycles of once-daily ibrutinib 420 mg or ibrutinib 840 mg. The 840 mg dose was discontinued after enrolment had begun because comparable activity of the doses has been shown." i.e. the appropriate dosage was still being determined initially.

healthunlocked.com/cllsuppo...

Open label means both the researchers and participants know which treatment is being administered.

Neil

Today's photo shows some galahs (rose-breasted cockatoos) feeding in a local park. If an Australian calls you a galah or perhaps a silly galah, it's generally not a complimentary term:

australiandictionary.net/galah

John Williamson (an Australian Country singer-songwriter) uses the phrase in his first hit from 1970 'Old Man Emu'. John is old enough to qualify for the above Ibrutinib trial (not that he has CLL to my knowledge) and I respect his decision to keep his Aussie accent despite the pressures to lose it to further his singing career overseas.

Have a listen if you'd like to hear a fun song by someone with a genuine Aussie accent:

youtube.com/watch?v=iYjrhj_...

Written by
AussieNeil profile image
AussieNeil
Partner
To view profiles and participate in discussions please or .
Read more about...
1 Reply

:-)

Not what you're looking for?

You may also like...

Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL

"This Phase Ib/IIa study is a multicenter open label trial of the combination of IPH2201 and...
AussieNeil profile image
Partner

Use of MRD Status Following Obinutuzumab/Ibrutinib to Guide Subsequent Intensification of Therapy in CLL

August 6, 2019 In this 2-part, single-arm, open-label, multicenter trial (Clinical Trials.gov...
Jm954 profile image
Administrator

BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies

Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
Jm954 profile image
Administrator

Zanubrutinib-Gazyva Shows Promise for CLL/SLL

June 25, 2019 Zanubrutinib (BGB-3111) is an investigational small molecule inhibitor of Bruton’s...
Jm954 profile image
Administrator

Treatment-naive or relapsed CLL patients will soon have zanubrutinib/Brukinsa as a treatment option in the EU

The EC approval is based on positive results from two Phase 3 clinical trials: SEQUOIA...
AussieNeil profile image
Partner